# Metropolis Healthcare (NSE: METROPOLIS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/METROPOLIS · Pivot · prices to 22 Oct 2026

Metropolis Healthcare (NSE: METROPOLIS) closed at ₹532.25 on 22 Oct 2026, down 0.03% on the day. With a market capitalisation of ₹11,035 Cr, it ranks 529th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 57.9× trailing earnings, against a return on equity of 12.6% in FY26. Over the past year the share price has risen 9.2%. Its 52-week range is ₹412.25 (2 Apr 2026) to ₹609.05 (30 Jul 2026); the last close is 12.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹450 Cr (+16.6% year on year) and net profit ₹57 Cr (+25.7%), on a consolidated basis. Promoters held 48.86% of the company as of 30 Jun 2026; 1.18% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹532.25 |
| Market cap | ₹11,035 Cr |
| P/E (trailing) | 57.9 |
| ROE | 12.6% (FY26) |
| ROCE | 16.2% (FY26) |
| Debt to equity | 0.01 |
| 52-week high | ₹609.05 (30 Jul 2026) |
| 52-week low | ₹412.25 (2 Apr 2026) |
| 1-year return | +9.2% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹450 Cr | +16.6% | ₹57 Cr | +25.7% | ₹2.73 |
| Q4 FY26 | ₹425 Cr | +23.0% | ₹51 Cr | +74.3% | ₹2.46 |
| Q3 FY26 | ₹406 Cr | +25.8% | ₹42 Cr | +33.7% | ₹7.99 |
| Q2 FY26 | ₹429 Cr | +22.7% | ₹53 Cr | +13.3% | ₹10.17 |
| Q1 FY26 | ₹386 Cr | +23.2% | ₹45 Cr | +18.7% | ₹8.70 |
| Q4 FY25 | ₹345 Cr | +4.3% | ₹29 Cr | −20.0% | ₹5.69 |
| Q3 FY25 | ₹323 Cr | +10.9% | ₹31 Cr | +15.3% | ₹6.12 |
| Q2 FY25 | ₹350 Cr | +13.4% | ₹47 Cr | +31.0% | ₹9.08 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,331 Cr | ₹146 Cr |
| FY24 | ₹1,208 Cr | ₹128 Cr |
| FY23 | ₹1,148 Cr | ₹143 Cr |
| FY22 | ₹1,228 Cr | ₹215 Cr |
| FY21 | ₹998 Cr | ₹183 Cr |
| FY20 | ₹856 Cr | ₹128 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 48.86%
- Foreign institutions: 11.03%
- Domestic institutions: 35.12%
- Non-institutions: 4.99%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [CORONA Remedies](https://app.pivotnow.in/stock/CORONA) | ₹2,024.70 | ₹12,500 Cr | 66.8 | 24.8% |
| [Rainbow Childrens Medicare](https://app.pivotnow.in/stock/RAINBOW) | ₹1,205.70 | ₹12,245 Cr | 43.9 | — |
| [Sudeep Pharma](https://app.pivotnow.in/stock/SUDEEPPHRM) | ₹984.90 | ₹11,124 Cr | 66.2 | — |
| [Akums Drugs and Pharmaceuticals](https://app.pivotnow.in/stock/AKUMS) | ₹690.85 | ₹10,874 Cr | 41.5 | — |
| [Park Medi World](https://app.pivotnow.in/stock/PARKHOSPS) | ₹220.45 | ₹9,522 Cr | 32.1 | — |
| [Blue Jet Healthcare](https://app.pivotnow.in/stock/BLUEJET) | ₹499.60 | ₹9,456 Cr | 35 | — |

## Questions and answers

### What is the share price of Metropolis Healthcare today?

Metropolis Healthcare (NSE: METROPOLIS) last closed at ₹532.25 on 22 Oct 2026. Its 52-week high is ₹609.05 and its 52-week low is ₹412.25.

### What is the market cap of Metropolis Healthcare?

Metropolis Healthcare's market capitalisation is ₹11,035 Cr (₹11,035 Cr) at the 22 Oct 2026 close, ranking 529th among the NSE companies Pivot tracks.

### What is the P/E ratio of Metropolis Healthcare?

Metropolis Healthcare trades at a trailing P/E of 57.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.9.

### What is the ROE and ROCE of Metropolis Healthcare?

Return on equity was 12.6% in FY26 and return on capital employed was 16.2% in FY26 (consolidated figures).

### Is Metropolis Healthcare a debt-free company?

Metropolis Healthcare is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### What were Metropolis Healthcare's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Metropolis Healthcare reported revenue of ₹450 Cr, +16.6% year on year, and net profit of ₹57 Cr, +25.7% year on year.

### How has Metropolis Healthcare stock performed over the last year?

Metropolis Healthcare's share price has risen 9.2% over the past year, −6.5% over three months and −11.1% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Metropolis Healthcare?

As of 30 Jun 2026: promoters 48.86%, foreign institutions 11.03%, domestic institutions 35.12%, non-institutions 4.99%. 1.18% of promoter shares were pledged.

### Who are Metropolis Healthcare's competitors?

The listed Pharma & Healthcare companies closest to Metropolis Healthcare by market cap are CORONA Remedies, Rainbow Childrens Medicare, Sudeep Pharma, Akums Drugs and Pharmaceuticals, Park Medi World and Blue Jet Healthcare.

### Is Metropolis Healthcare a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Metropolis Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on METROPOLIS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.